Table 2.
Element | Drugs | Requirement (examples) |
---|---|---|
Documentation of safe use | Alvimopan (Entereg) | Dispensed only at hospitals that perform bowel resections, no more than 15 doses per patient |
Isotretinoin (Accutane (off market) and generic) | Negative pregnancy test, two documented forms of contraception (iPLEDGE) | |
Lenalidomide (Revlimid) and all thalidomide analogs | Negative pregnancy tests | |
Vigabatrin (Sabril) | Baseline ophthalmologic assessment within 4 weeks then every 3 months after | |
Prescriber training and/or certification | Buprenorphine/naloxone (Suboxone) | Complete course and certification |
Fentanyl transmucosal (Actiq, Fentora, and several others) | Pharmacy check prescriber certification with a sponsor database | |
Erythropoiesis-stimulating agents (ESA): Aranesp (darbepoetin alfa); Epogen and Procrit (epoetin alfa) | Provider and hospital designee must complete training (APPRISE Oncology Program) | |
Safety monitoring | Olanzapine long-acting injection (Zyprexa Relprevv) Clozapine (Clozaril) |
Continuous observation for 3 h post-injection (olanzapine) Complete blood count (clozapine) |
Registries | Isotretinoin (generic only) Vigabatrin (Sabril) |
iPLEDGE program SHARE program |
Restricted distribution | Oxybate (Xyrem) Vigabatrin (Sabril) |
Distribution from single national pharmacy (Xyrem) |